BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celsis International PLC  (CEL.L) Acquires In Vitro Technologies For $30 Million


8/8/2006 10:27:37 AM

CHICAGO--(BUSINESS WIRE)--Aug. 8, 2006--Celsis International plc, a Chicago-based life science products and services company, today announced the acquisition of In Vitro Technologies, Inc. (IVT) for $30 million in cash and an earn-out consideration capped at $5 million. The acquisition of IVT adds a world-class suite of products and services for the in vitro ADME toxicology market to the Celsis portfolio.

Based in Baltimore, Maryland, IVT supplies products and services to improve the drug discovery and development process. IVT's product portfolio includes proprietary ADME-Tox products including fresh and cyropreserved cells and enzymes. An estimated 50 percent of drug candidates fail in clinical trials due to unanticipated pharmacokinetic and toxicology issues. The use of IVT's broad range of tools has resulted in the selection of optimum candidates for the clinical trial stage.

The integration of IVT into Celsis creates significant value for customers of both companies through the combination of complementary products and services and through the expertise of the collective employee base of seasoned scientists and client support specialists.

"With the acquisition of In Vitro Technologies Inc., Celsis has expanded its business through an improved product and services portfolio and created clear cross-selling opportunities which we expect to deliver material growth in the coming years," said Jay LeCoque, CEO of Celsis International plc. "Celsis is well positioned to continue its track record of strong growth both organically and by acquisition."

"We could not have hoped for a better strategic partner than Celsis," said Paul Silber, Ph.D, founder of IVT. "The synergy created by joining forces will create a strong team with great potential for future growth. This new combination will provide our respective customers with great value through a significantly expanded product and service offering. I very much look forward to working with the team at Celsis."

Celsis International plc

Celsis International plc provides value enhancing products and services to the pharmaceutical, biopharmaceutical, personal care and beverage industries through its three business areas; rapid detection systems, analytical services and in vitro technologies. The company is listed on the London Stock Exchange (CEL.L).

More information can be found at www.celsis.com.

Contact: for Celsis International plc Murad Sabzali, 630-400-3042 msabzali@chempetitive.com

Source: Celsis International plc

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES